Madrigal Pharmaceuticals
499,71 $Variazione rispetto alla chiusura precedente: −0,84%Variazione assoluta: −4,25 $
Profilo dell'azienda
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Descrizione disponibile in inglese.
Dati societari
- Settore
- Salute
- Industria
- Biotechnology
- Paese
- Stati Uniti
- Sede
- 1001 Conshohocken State Road, 19428, West Conshohocken
- Dipendenti
- 915
- Quotazione
- MDGL · NASDAQ
- Valuta
- USD
- Sito web
- madrigalpharma.com